• LinkedIn
  • YouTube
  • Facebook
  • Twitter
InnoSer
  • CRO Services
        • Drug Development
          • Target Validation
          • Hit to Lead
          • Lead Optimization
          • Preclinical Development Services
          • Pathology
          • Mouse Models
        • Facility Management & Support
          • Colony Management
          • Facility Management
          • Sanitation and Cryopreservation
          • ISAP – InnoSer Acceleration Program
  • Disease Models
    • Disease Areas
    • Cardio-metabolic
    • Nephrology
    • Rare Diseases
      • Fragile X syndrome (Fmr1)
      • Vanishing White Matter (Eif2b)
      • Charcot Marie Tooth Disease Type 1A (PMP22)
      • Infantile Epileptic Encephalopathy (STXBP1/Munc18-1)
      • Polycystic Kidney Disease
    • Neurology
      • Alzheimer’s Disease
      • Parkinson’s Disease
      • ALS Disease
      • Multiple Sclerosis
      • Spasticity
      • Ageing
    • Immuno-oncology
  • Resources
    • News
    • Conferences
    • Privacy Policy
  • About
    • About InnoSer
    • Contact
    • Team
    • Scientific Board
    • 3R's Policy
    • Vacancies
Select Page
TRANSCEND: developing a novel platform integrating organoid and humanized in vivo models for Parkinson’s Disease

TRANSCEND: developing a novel platform integrating organoid and humanized in vivo models for Parkinson’s Disease

Jun 29, 2021

The TRANSCEND project aims to tackle the current limitations of drug development for Parkinson’s Disease by the integration of an innovative in vitro brain organoid model and a humanized in vivo mouse model. This unique two-step platform supports InnoSer’s aspiration...

Recent Posts

  • Novel Translational Readout: Auditory Event-Related Potentials EEG-Recording in Fragile X Syndrome Model 
  • Accelerating ALS Drug Development: InnoSer’s Available In Vivo Models for Preclinical Research
  • In Vitro & In Vivo Parkinson’s Disease Models: Understanding Their Role in Preclinical Drug Development 
  • Choosing The Right ADPKD Model for Advancing your Rare Disease Research
  • A novel inflammation and fibrosis model in the field of NASH & drug repurposing

Subscribe To Newsletter

By signing up, you agree to receive promotional emails from InnoSer.

You can unsubscribe at any time by clicking the link in the footer of our emails. For information about our privacy practices, please check our privacy page.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing.

  • LinkedIn
  • YouTube
  • Facebook
  • Twitter
Copyright InnoSer 2020-2022
This website uses cookies to improve your experience. Information about your use of the site is also shared with Google for analyzing traffic to this site. You can opt-out if you wish. Cookie settingsACCEPT Privacy policy
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT